Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids

19 november 2026 bijgewerkt door: Hua Li

Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial

This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.

The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.

The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.

Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.

Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.

Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.

Studietype

Ingrijpend

Inschrijving (Geschat)

110

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100024
        • Beijing Chao Yang Hospital, Capital Medical University
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

20 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
  • Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
  • Age 20 to 50 years and premenopausal, with or without future fertility plans.
  • No contraindications to laparoscopic surgery.

Exclusion Criteria:

  • Concomitant submucosal fibroids classified as FIGO types 0-2.
  • Findings suspicious for malignancy on preoperative assessment.
  • Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
  • Known severe hepatic or renal dysfunction.
  • Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
  • Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
  • Acute infection.
  • Inability to sign the informed consent form.
  • Known or suspected poor adherence that would prevent completion of the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Laparoscopic Ultrasound-Guided Myomectomy

Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal.

During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety.

Actieve vergelijker: Conventional Laparoscopic Myomectomy

Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance.

Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Fibroid Removal Rate
Tijdsspanne: During surgery and within 3 months after surgery

For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100.

During surgery and within 3 months after surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Operative Time
Tijdsspanne: During surgery

Duration of the surgical procedure, measured in minutes.

During surgery
Residual Uterine Fibroid Rate
Tijdsspanne: 3 months after surgery (+/- 14 days)

Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100.

3 months after surgery (+/- 14 days)
Difference Between Removed and Preoperatively Identified Fibroid Counts
Tijdsspanne: Preoperative assessment and during surgery

For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging.

Preoperative assessment and during surgery
Estimated Intraoperative Blood Loss
Tijdsspanne: During surgery

Estimated volume of blood lost during surgery, measured in milliliters.

During surgery
Participants With Intraoperative Complications
Tijdsspanne: During surgery

Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury.

During surgery
Participants With Postoperative Complications
Tijdsspanne: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)

Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits.

From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
Postoperative Length of Hospital Stay
Tijdsspanne: Perioperative

Time from completion of surgery to hospital discharge, measured in days.

Perioperative
Postoperative Pain Score
Tijdsspanne: 2 and 6 hours after surgery

Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain.

2 and 6 hours after surgery
Time to First Postoperative Ambulation
Tijdsspanne: Perioperative

Time from completion of surgery to first postoperative ambulation, measured in hours.

Perioperative
Time to First Postoperative Flatus
Tijdsspanne: Perioperative

Time from completion of surgery to first passage of flatus, measured in hours.

Perioperative
Duration of Postoperative Uterotonic Treatment
Tijdsspanne: Perioperative

Duration of postoperative uterotonic medication use, measured in hours.

Perioperative
Time to Postoperative Drain Removal
Tijdsspanne: Perioperative

Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed.

Perioperative
Participants With Postoperative Urinary Dysfunction
Tijdsspanne: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Participants With Postoperative Bowel Dysfunction
Tijdsspanne: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)

Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit.

1, 3, and 12 months after surgery (each visit window: +/- 14 days)
Change From Baseline in Female Sexual Function Index Score
Tijdsspanne: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function.

Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Oswestry Disability Index Score
Tijdsspanne: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)

Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability.

Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
Change From Baseline in Zung Self-Rating Anxiety Scale Score
Tijdsspanne: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety.

Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
15-Item Quality of Recovery Questionnaire Score
Tijdsspanne: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated.

Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 januari 2029

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

28 oktober 2026

Eerst ingediend dat voldeed aan de QC-criteria

19 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

19 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 2026-sci-844-1

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

There is no plan to share de-identified individual participant data with researchers outside the study team.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .